UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 40

Sortiert nach

Comparison of patient-reported breast, arm, and shoulder symptoms and body image after radiotherapy for early breast cancer: 5-year follow-up in the randomised Standardisation of Breast Radiotherapy (START) trials

The lancet oncology, 2010-03, Vol.11 (3), p.231-240

2010

Volltextzugriff (PDF)

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial

The lancet oncology, 2017-07, Vol.18 (7), p.929-945

2017

Volltextzugriff (PDF)

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study

The lancet oncology, 2007-02, Vol.8 (2), p.119-127

2007

Volltextzugriff (PDF)

Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial

The Lancet (British edition), 2017-09, Vol.390 (10099), p.1048-1060

2017

Volltextzugriff (PDF)

In Regard to Vaidya et al

International journal of radiation oncology, biology, physics, 2015-08, Vol.92 (5), p.954-955

2015

Volltextzugriff (PDF)

Implementation of platform trials in the COVID-19 pandemic: A rapid review

Contemporary clinical trials, 2022-01, Vol.112, p.106625-106625, Article 106625

2022

Volltextzugriff (PDF)

Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial – Authors' reply

The Lancet (British edition), 2024-05, Vol.403 (10438), p.1752-1752

2024

Volltextzugriff (PDF)

Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial

Radiotherapy and oncology, 2016-07, Vol.120 (1), p.114-118

2016

Volltextzugriff (PDF)

Accelerated partial breast irradiation: more questions than answers?

The Lancet (British edition), 2019-12, Vol.394 (10215), p.2127-2129

2019

Volltextzugriff (PDF)

Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial

The lancet oncology, 2006-06, Vol.7 (6), p.467-471

2006

Volltextzugriff (PDF)

Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial

The Lancet (British edition), 2023-06, Vol.401 (10394), p.2124-2137

2023

Volltextzugriff (PDF)

Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial

Radiotherapy and oncology, 2019-05, Vol.134, p.220-230

2019

Volltextzugriff (PDF)

Radiotherapy for breast cancer, the TARGIT-A trial

The Lancet (British edition), 2014-05, Vol.383 (9930), p.1716-1717

2014

Volltextzugriff (PDF)

Is breast seroma after tumour resection associated with patient-reported breast appearance change following radiotherapy? Results from the IMPORT HIGH (CRUK/06/003) trial

Radiotherapy and oncology, 2019-07, Vol.136, p.190-196

2019

Volltextzugriff (PDF)

Getting our ducks in a row: The need for data utility comparisons of healthcare systems data for clinical trials

Contemporary clinical trials, 2024-06, Vol.141, p.107514-107514, Article 107514

2024

Volltextzugriff (PDF)

Targeted radiotherapy for early breast cancer – Authors' reply

The Lancet (British edition), 2018-01, Vol.391 (10115), p.27-28

2018

Volltextzugriff (PDF)

Late effects of breast radiotherapy

The Lancet (British edition), 2014-04, Vol.383 (9926), p.1383-1384

2014

Volltextzugriff (PDF)

Intraoperative radiotherapy for early breast cancer

The Lancet (British edition), 2010-10, Vol.376 (9747), p.1142-1142

2010

Volltextzugriff (PDF)

The MARS feasibility trial: conclusions not supported by data – Authors' reply

The lancet oncology, 2011-11, Vol.12 (12), p.1094-1095

2011

Volltextzugriff (PDF)

Corrigendum to “The impact of age and clinical factors on quality of life in early breast cancer: An analysis of 2208 women recruited to the UK START Trial (Standardisation of Breast Radiotherapy Trial)”

Breast (Edinburgh), 2008, Vol.17 (1), p.115-115

2008

Volltextzugriff (PDF)

Breast cancer and hormone-replacement therapy: the Million Women Study

The Lancet (British edition), 2003-10, Vol.362 (9392), p.1328-1328

Garton, Mark

2003

Volltextzugriff (PDF)

1 – 25 von 40

Suche als RSS-Feed

Aktive Filter

ThemaAged

KollektionElsevier ScienceDirect Journals Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(40)

Sprache

Englisch
(40)

Erscheinungsjahr

n.n

Thema

Humans
(32)
Female
(28)
Life Sciences & Biomedicine
(28)
Science & Technology
(28)
Breast Cancer
(25)
Oncology
(14)
Patients
(14)
Breast Neoplasms - Pathology
(13)
Breast Neoplasms - Radiotherapy
(12)
General & Internal Medicine
(12)
Medical Research
(12)
Medicine, General & Internal
(12)
Clinical Trials
(11)
Radiation Therapy
(11)
Cancer Therapies
(10)
Hematology, Oncology And Palliative Medicine
(10)
Tumors
(10)
Womens Health
(10)
Breast Neoplasms - Surgery
(9)
Breast Neoplasms - Drug Therapy
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial

Comparison of patient-reported breast, arm, and shoulder symptoms and body image after radiotherapy for early breast cancer: 5-year follow-up in the randomised Standardisation of Breast Radiotherapy (START) trials

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial

Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial

In Regard to Vaidya et al

Implementation of platform trials in the COVID-19 pandemic: A rapid review

Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial – Authors' reply

Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial

Accelerated partial breast irradiation: more questions than answers?

Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial

Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial

Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial

Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant

Radiotherapy for breast cancer, the TARGIT-A trial

Is breast seroma after tumour resection associated with patient-reported breast appearance change following radiotherapy? Results from the IMPORT HIGH (CRUK/06/003) trial

Getting our ducks in a row: The need for data utility comparisons of healthcare systems data for clinical trials

Targeted radiotherapy for early breast cancer – Authors' reply

Late effects of breast radiotherapy

Intraoperative radiotherapy for early breast cancer

The MARS feasibility trial: conclusions not supported by data – Authors' reply

Corrigendum to “The impact of age and clinical factors on quality of life in early breast cancer: An analysis of 2208 women recruited to the UK START Trial (Standardisation of Breast Radiotherapy Trial)”

Breast cancer and hormone-replacement therapy: the Million Women Study

Aktive Filter

Suchergebnisse filtern